Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Renal Cell Carcinoma
With increasing overlap between advanced clear cell and non-clear cell RCC management with IO+TKI therapy, are there subtypes of non-clear cell RCC for which you would not use this approach?
Related Questions
Is there still a role for mTOR inhibitors in metastatic RCC in the immunotherapy/TKI era?
How would you approach a patient with metastatic renal cell carcinoma who developed a STEMI while on TKI (Lenvatinib) and immunotherapy combination?
How do you manage anemia associated with belzutifan therapy?
What perioperative systemic therapy would you use for a patient with oligometastatic clear cell RCC with a bony metastasis at risk for fracture?
What adjuvant therapy, if any, is best for mucinous tubular and spindle cell carcinoma of the kidney?
How often do you monitor for pancreatitis (check lipase/amylase) while on Axitinib?
Would you offer adjuvant immunotherapy in a patient with high risk RCC with new/worsening post-op renal dysfunction and CrCl<30?
How do you manage hypoxia induced by belzutifan?
What is your approach to surveillance in patients with no evidence of disease after treatment of oligometastatic renal cell carcinoma?
Would you offer adjuvant immunotherapy (pembrolizumab) for chromophobe RCC with R1 resection?
